CERELA   05438
CENTRO DE REFERENCIA PARA LACTOBACILOS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Immunomodulation and riboflavin production by lactic acid bacteria reduce intestinal damage in a murine model of 5-fluorouracil-induced mucositis
Autor/es:
SAVOY DE GIORI, G.,; LEVIT R.,; LEBLANC J-G.; DE MORENO DE LEBLANC, A
Lugar:
Egmond aan Zee
Reunión:
Simposio; 12 th International Symposium on Lactic Acid Bacteria.; 2017
Institución organizadora:
Federation of European Microbiological Societies and Netherlands Institute for Microbiology
Resumen:
Intestinal mucositis (IM) is a side effect of cancer therapy characterized by ulceration, inflammation and hemorrhage throughout the gastrointestinal tract. 5-Fluorouracil (5-FU), one of the most commonly used chemotherapeutic agents, can also affect healthy cells located throughout the body such as the epithelia of the gastrointestinal tract. Certain probiotic strains with anti-inflammatory and anti-oxidant properties could represent an alternative for this clinical condition. Previously, it has been reported that the immunomodulatory Streptococcus thermophilus CRL807 (St CRL807), and the riboflavin producing Lactobacillus plantarum CRL2130 (Lp CRL2130) attenuated TNBS-induced colitis in mice, suggesting their potential use in mucositis. The aim of this study was to investigate the protective effects of St CRL807 and Lp CRL2130 on 5-FU-induced IM in a mouse model. Mice were injected i.p. with saline (healthy control) or 5-FU daily during six days. Mice were orally given saline (5-FU group), St CRL807, Lp CRL 2130, Lp CRL 725 (non-riboflavin producing strain from which Lp CRL2130 was derived), or commercial riboflavin. Body weight, diarrhea score, serum cytokines and intestinal morphology and histopathology were assessed. St CRL807 and Lp CRL2130 significantly reduced the diarrhea score, reversed the histopathological changes induced by 5-FU (evidenced by increased villus hight/crypt depth ratio), and reduced the inflammation with increased IL-10/IL-17; IL-10/INF-γ; IL-10/TNF-α ratio in serum by reversing the inflammatory cytokine profile associated to 5-FU. Commercial vitamin, at the same concentration produced by Lp CRL2130, showed similar beneficial effects; whereas, Lp CRL725 did not show significant differences compared to 5-FU control. In conclusion, our results show that oral administration of riboflavin producing strain Lp CRL2130 or the anti-inflammatory strain St CRL807 have potential to prevent 5-FU-induced intestinal mucositis.